spacer
spacer

PDBsum entry 1oyq

Go to PDB code: 
protein ligands metals links
Hydrolase PDB id
1oyq

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
223 a.a. *
Ligands
SO4
T87
Metals
_CA
Waters ×169
* Residue conservation analysis
PDB id:
1oyq
Name: Hydrolase
Title: Trypsin inhibitor complex
Structure: Trypsin, cationic. Chain: a. Synonym: beta-trypsin. Ec: 3.4.21.4
Source: Bos taurus. Cattle. Organism_taxid: 9913. Organ: pancreas
Resolution:
1.90Å     R-factor:   0.176     R-free:   0.221
Authors: H.Nar
Key ref:
H.Nar et al. (2001). Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure, 9, 29-37. PubMed id: 11342132 DOI: 10.1016/S0969-2126(00)00551-7
Date:
07-Apr-03     Release date:   29-Apr-03    
Supersedes: 1g34
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
P00760  (TRY1_BOVIN) -  Serine protease 1 from Bos taurus
Seq:
Struc:
246 a.a.
223 a.a.
Key:    Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.3.4.21.4  - trypsin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa.

 

 
DOI no: 10.1016/S0969-2126(00)00551-7 Structure 9:29-37 (2001)
PubMed id: 11342132  
 
 
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
H.Nar, M.Bauer, A.Schmid, J.M.Stassen, W.Wienen, H.W.Priepke, I.K.Kauffmann, U.J.Ries, N.H.Hauel.
 
  ABSTRACT  
 
BACKGROUND: A major current focus of pharmaceutical research is the development of selective inhibitors of the blood coagulation enzymes thrombin or factor Xa to be used as orally bioavailable anticoagulant drugs in thromboembolic disorders and in the prevention of venous and arterial thrombosis. Simultaneous direct inhibition of thrombin and factor Xa by synthetic proteinase inhibitors as a novel approach to antithrombotic therapy could result in potent anticoagulants with improved pharmacological properties. RESULTS: The binding mode of such dual specific inhibitors of thrombin and factor Xa was determined for the first time by comparative crystallography using human alpha-thrombin, human des-Gla (1--44) factor Xa and bovine trypsin as the ligand receptors. The benzamidine-based inhibitors utilize two different conformations for the interaction with thrombin and factor Xa/trypsin, which are evoked by the steric requirements of the topologically different S2 subsites of the enzymes. Compared to the unliganded forms of the proteinases, ligand binding induces conformational adjustments of thrombin and factor Xa active site residues indicative of a pronounced induced fit mechanism. CONCLUSION: The structural data reveal the molecular basis for a desired unselective inhibition of the two key components of the blood coagulation cascade. The 4-(1-methyl-benzimidazole-2-yl)-methylamino-benzamidine moieties of the inhibitors are able to fill both the small solvent accessible as well as the larger hydrophobic S2 pockets of factor Xa and thrombin, respectively. Distal fragments of the inhibitors are identified which fit into both the cation hole/aromatic box of factor Xa and the hydrophobic aryl binding site of thrombin. Thus, binding constants in the medium-to-low nanomolar range are obtained against both enzymes.
 
  Selected figure(s)  
 
Figure 2.
Figure 2. Experimental Evidence for the Bound Conformation of the Ligands to their Protein ReceptorsDifference electron density maps (contoured at 2s) of BIBT0871 (left column) and BIBR1109 (right column) in the active sites of factor Xa, trypsin and thrombin (from top to bottom) superimposed on the final structures

 
  The above figure is reprinted by permission from Cell Press: Structure (2001, 9, 29-37) copyright 2001.  
  Figure was selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
18175308 C.Schalon, J.S.Surgand, E.Kellenberger, and D.Rognan (2008).
A simple and fuzzy method to align and compare druggable ligand-binding sites.
  Proteins, 71, 1755-1778.  
18680100 N.Singh, and J.M.Briggs (2008).
Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites.
  Biopolymers, 89, 1104-1113.  
18266362 R.Abel, T.Young, R.Farid, B.J.Berne, and R.A.Friesner (2008).
Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.
  J Am Chem Soc, 130, 2817-2831.  
16700049 C.A.Bottoms, T.A.White, and J.J.Tanner (2006).
Exploring structurally conserved solvent sites in protein families.
  Proteins, 64, 404-421.  
16923021 K.M.Bromfield, N.S.Quinsey, P.J.Duggan, and R.N.Pike (2006).
Approaches to selective peptidic inhibitors of factor Xa.
  Chem Biol Drug Des, 68, 11-19.  
15139037 M.Almlöf, B.O.Brandsdal, and J.Aqvist (2004).
Binding affinity prediction with different force fields: examination of the linear interaction energy method.
  J Comput Chem, 25, 1242-1254.  
12479872 J.P.Ludeman, R.N.Pike, K.M.Bromfield, P.J.Duggan, J.Cianci, B.Le Bonniec, J.C.Whisstock, and S.P.Bottomley (2003).
Determination of the P1', P2' and P3' subsite-specificity of factor Xa.
  Int J Biochem Cell Biol, 35, 221-225.  
12437122 D.Rauh, S.Reyda, G.Klebe, and M.T.Stubbs (2002).
Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.
  Biol Chem, 383, 1309-1314.  
11854268 N.S.Quinsey, J.C.Whisstock, B.Le Bonniec, V.Louvain, S.P.Bottomley, and R.N.Pike (2002).
Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide.
  J Biol Chem, 277, 15971-15978.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer